



July 15, 2021

RE: Early Termination of SHP648-101

After careful evaluation, Takeda has made the decision not to pursue further development of the SHP648 (TAK-748) program and to close the SHP648-101 study.

As of the date of the decision to close the study, two subjects were screened, no subjects were enrolled, and no subjects were dosed with SHP648. As no subjects were dosed with Investigational Product, safety and/or efficacy cannot be evaluated.

The risk/benefit profile of SHP648 has not changed, and the decision to end this study and close all participating sites is not due to any safety concerns.

Regards,

[Redacted signature block]